Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 6:54 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,629 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: In The Mix Clear all
Completed Phase 2 Interventional

DMT310-003 Topical in the Treatment of Acne Vulgaris

NCT04106778
View directory record Official record
Conditions
Acne Vulgaris
Interventions
DMT310, Placebo
Drug
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
12 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2020 · Synced Oct 30, 2026, 6:54 PM EDT
Recruiting Not applicable Interventional

Efficacy of Perioperative Opioid Sparing Techniques on Time to Initiation of Chemotherapy

NCT07153614
View directory record Official record
Conditions
Perioperative Opioid Sparing Techniques
Interventions
Intrathecal Morphine Block, Bilateral Quadratus Lumborum Block, Bilateral Transverse Abdominis Plane Block
Procedure
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 30, 2026, 6:54 PM EDT
Completed Phase 3 Interventional Results available

Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors

NCT00369785
View directory record Official record
Conditions
Brain Tumors, Metastatic Disease
Interventions
donepezil hydrochloride, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
16
States / cities
Wichita, Kansas • Lewiston, Maine • Hooksett, New Hampshire + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 30, 2026, 6:54 PM EDT
Completed Phase 4 Interventional Results available

Comparing Subsartorial Saphenous Nerve Blocks With and Without Dexamethasone for Anterior Cruciate Ligament Reconstruction

NCT01586806
View directory record Official record
Conditions
Anterior Cruciate Ligament Reconstruction, Regional Anesthesia, Saphenous Nerve Block
Interventions
Bupivacaine Only, Bupivacaine with 1 mg of Dexamethasone, Bupivacaine with 4 mg of Dexamethasone
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
16 Years to 65 Years
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Oct 30, 2026, 6:54 PM EDT
Completed Phase 2 Interventional Results available

Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer

NCT00071058
View directory record Official record
Conditions
Adrenal Cortex Neoplasms
Interventions
XR9576 (Tariquidar)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2012 · Synced Oct 30, 2026, 6:54 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Breath Analysis & Malnutrition

NCT06115148
View directory record Official record
Conditions
Malnutrition
Interventions
Feeding, Fasting
Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 95 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 30, 2026, 6:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dietary Assessment Study Via Digital Images

NCT03267004
View directory record Official record
Conditions
Diet Habit
Interventions
Dietary Assessment of Meal A using images taken by Sony Smarteyeglass, Dietary Assessment of Meal B using Images taken by Sony Smarteyeglass
Device
Lead sponsor
The University of Tennessee, Knoxville
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 30, 2026, 6:54 PM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors

NCT00003484
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Neuroblastoma
Interventions
carmustine, irinotecan hydrochloride, surgical procedure, iodine I 131 monoclonal antibody 81C6
Drug · Procedure · Radiation
Lead sponsor
Darell D. Bigner, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Oct 30, 2026, 6:54 PM EDT
Completed Phase 1 Interventional

Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

NCT00598169
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, bortezomib, carboplatin, dexamethasone, etoposide, ifosfamide, polymerase chain reaction, western blotting
Biological · Drug · Genetic
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Oct 30, 2026, 6:54 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Effect of Addition of Steroids on Duration of Analgesia

NCT04126824
View directory record Official record
Conditions
Uterine Fibroids, Adenomyosis
Interventions
Triamcinolone, Bupivacaine, Iohexol contrast
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
30 Years to 60 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Westwood, Los Angeles, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 30, 2026, 6:54 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults

NCT02935686
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos4.HIV, Clade C gp140 plus adjuvant, Clade C gp140/Mosaic gp140 plus adjuvant, Placebo, gp140 HIV Bivalent Vaccine
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 30, 2026, 6:54 PM EDT
Terminated Phase 1 Interventional

VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma

NCT00516282
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
CLORETAZINE, temozolomide
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 26, 2011 · Synced Oct 30, 2026, 6:54 PM EDT
Completed Phase 4 Interventional Results available

Intranasal Bevacizumab for HHT-Related Epistaxis

NCT02389959
View directory record Official record
Conditions
HHT, Hereditary Hemorrhagic Telangiectasia, Epistaxis, Nose Bleeds, Nasal Bleeding
Interventions
Bevacizumab, Placebo (Saline)
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 30, 2026, 6:54 PM EDT
Completed No phase listed Observational

Study of Tissue and Blood Samples From Patients With Low-Grade Glioma

NCT01004523
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
fluorescence in situ hybridization, loss of heterozygosity analysis, polymerase chain reaction, flow cytometry, immunohistochemistry staining method
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2013
U.S. locations
38
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Clive, Iowa + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Oct 30, 2026, 6:54 PM EDT
Completed Phase 1 Interventional

Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas

NCT02238496
View directory record Official record
Conditions
Brain Tumor, Recurrent, Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Mixed Glioma
Interventions
Cytoreductive surgery, Perifosine, Temsirolimus
Procedure · Drug
Lead sponsor
Andrew B Lassman, MD
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Oct 30, 2026, 6:54 PM EDT
Completed Not applicable Interventional Results available

Biobehavioral Mechanisms of Glucose Variability

NCT01835964
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Glucose Variability Observation
Procedure
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 30, 2026, 6:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Development, Feasibility and Acceptability of Fathers and Babies (FAB): A Pilot Study

NCT03427528
View directory record Official record
Conditions
Perinatal Depression, Postpartum Depression, Depression
Interventions
Fathers and Babies (FAB), MB 1-on-1 plus TXT
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 30, 2026, 6:54 PM EDT
Completed Phase 3 Interventional Results available

Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer

NCT00661999
View directory record Official record
Conditions
Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
darbepoetin alfa, ferrous sulfate, sodium ferric gluconate complex in sucrose, placebo
Biological · Dietary Supplement · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 17, 2011 · Synced Oct 30, 2026, 6:54 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of an Entrepreneurship Program for American-Indian Youth

NCT02157493
View directory record Official record
Conditions
Depressive Symptoms, Substance Use
Interventions
Arrowhead Business Group Curriculum, Recreational League Control Condition
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
13 Years to 15 Years
Enrollment
449 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Whiteriver, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 17, 2024 · Synced Oct 30, 2026, 6:54 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Black Forest Cocoa Flavanol Supplementation and Health Trial

NCT07747714
View directory record Official record
Conditions
Endothelial Function, Oxidative Stress, Inflamation, Vascular Health
Interventions
Cocoa Flavanol Supplement, Low-Flavanol Control Powder
Dietary Supplement
Lead sponsor
The Black Forest LLC
Industry
Eligibility
30 Years to 75 Years · Male only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 30, 2026, 6:54 PM EDT
Recruiting Not applicable Interventional

Clinical Trial Evaluating the Safety and Efficacy of Nucleus Pulposus Allograft in Participants With Degenerative Disc Disease

NCT06778447
View directory record Official record
Conditions
Degenerative Disc Disease, Disc Degeneration, Lumbar Discogenic Pain
Interventions
VIA Disc NP, Sham
Other
Lead sponsor
VIVEX Biologics, Inc.
Industry
Eligibility
22 Years to 85 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
19
States / cities
Napa, California • Santa Monica, California • Thornton, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 30, 2026, 6:54 PM EDT
Terminated Not applicable Interventional Results available

Celliant Socks to Increase Tissue Oxygenation and Complete Wound Closure in Diabetic Foot Wounds

NCT04709419
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
Celliant Diabetic Medical Socks, Control (placebo) Medical Socks
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
22 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 30, 2026, 6:54 PM EDT
Active, not recruiting Phase 1 Interventional

A Blood Stem Cell Transplant for Sickle Cell Disease

NCT03249831
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Disorder, Hemoglobinopathies, Thalassemia, Anemia, Sickle Cell
Interventions
Cyclophosphamide, Pentostatin, Rabbit anti-thymocyte globulin, Tacrolimus, Mycophenolate mofetil, CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 45 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 30, 2026, 6:54 PM EDT
Completed Phase 2 Interventional

PRebiotic to IMprovE Calcium Absorption

NCT03272542
View directory record Official record
Conditions
Obesity
Interventions
Prebiotic: soluble corn fiber, Placebo: maltodextrin
Dietary Supplement
Lead sponsor
San Francisco Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 75 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 30, 2026, 6:54 PM EDT